fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Lady Blazers Capture Second Region All 'A' Championship

MARION, Ky. (4/17/15) — The University Heights Academy softball team won its first Second Region All "A" Classic title… Read More

WellCare Gives $12,000 to Marshall County Initiative to Improve Youth Activity, Nutrition

KENTUCKY (4/16/15) — WellCare Health Plans, Inc. (NYSE: WCG), a leading provider of managed care services for… Read More
1 DOW 17,826.30
-279.47 (-1.54%)    
2 S&P 2,081.18
-23.81 (-1.13%)    
3 NASDAQ 4,931.81
-75.98 (-1.52%)    

Most Read This Week

April 13, 2015 6135

Three Juveniles, Adult Accused of Vandalizing…

by Deputy Will Coursey
April 14, 2015 4751

Several Juveniles Charged in Connection with Fight

by SurfKY News
April 16, 2015 3321

Crime Stoppers Fugitive of the Week – April 16,…

by Hopkinsville – Christian County Crime Stoppers
April 11, 2015 2952

Juvenile Injured When Struck by Vehicle

by Madisonville Police
April 17, 2015 2936

An Open Letter from an Addict

by Olivia Kirks

Most Read This Month

March 18, 2015 10040

UPDATE: Hanson Man Located in Henderson, Taken to…

by Trooper Stu Recke
April 02, 2015 8422

UPDATE: Madisonville Man Injured in Head-on…

by Doreen Dennis, SurfKY News

Stories Trending Now

April 17, 2015 2936

An Open Letter from an Addict

by Olivia Kirks
April 17, 2015 958

Madisonville Police Reports Released

by Rita Dukes Smith, SurfKY News Director
April 17, 2015 934

Two Charged in Connection with Powderly Firearms…

by SurfKY News
April 17, 2015 807

Police Officers Building Up Community by Helping…

by Doreen Dennis, SurfKY News
April 17, 2015 730

Hopkins County Sheriff's Reports Released

by SurfKY News
April 18, 2015 554

Man Charged with Attempting to Coerce Minor for…

by Madisonville Police Department
April 17, 2015 510

'The Bidding is On' at Annual Library Auction

by Tammy Holloway, SurfKY News
April 17, 2015 424

Brown Pitches Baseball to Series Opener over…

by UK Athletics
April 17, 2015 412

Free Seedling Plantings Available While Supplies…

by Amber Averitt, SurfKY News